← All trials
NCT06078969
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Sep 30, 2027
- Completion date
- Sep 30, 2027
- First posted
- Oct 12, 2023
- Last posted
- Oct 17, 2023
- Enrollment
- 118
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Second Military Medical UniversityLead sponsor
- Capital Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Henan Medical UniversityCollaborator
- Nanjing UniversityCollaborator
- Peking UniversityCollaborator
- Peking UniversityCollaborator
- Jilin UniversityCollaborator
- Second Military Medical UniversityReponsible party - principal investigator
- Nanchang UniversityCollaborator
- Southern Medical UniversityCollaborator
- Tianjin UniversityCollaborator
- Second Military Medical UniversitySponsor investigator
- Jinlin UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.